ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

September 18, 2023
Dr. Choy treated Yoki for 3 years after his diagnosis, allowing him more time with his family.

This article is written by Hilary Tetenbaum and published in USA Today.

---

The battle against cancer has always been a challenge. Despite the revolutionary advancements in medical science, the battle still continues to be challenging. When it comes to canine cancer, the process right from diagnosis to treatment and cure becomes even tougher due to the complexities involved. However, ImpriMed, a California-based AI-driven precision medicine company has embarked on a mission to revolutionize the realm of canine cancer treatment. Its proprietary technology identifies the best-suited drug(s) for individual canine cancer patients.  

In order to make its drug response predictions as accurate as possible, ImpriMed uses proprietary AI algorithms that rely on real-world clinical outcomes and patients’ live cell-based drug sensitivity data. This approach significantly helps oncologists by providing them with reliable predictions to choose the most suitable drugs for their patients. This method substantially eliminates the guesswork when it comes to drug selection and avoids unnecessary costs or side effects that might come with multiple drug trials. There are three major components in the service: Drug response and prognosis prediction, immune subtyping, and clonality analysis.

What sets ImpriMed apart from other players in the industry is its unique methodology and approach to canine cancer treatment. There are other companies doing precision medicine in veterinary oncology, and there are also companies utilizing AI in veterinary oncology. However, no other company in the veterinary oncology realm employs an AI-powered drug efficacy prediction the way ImpriMed uses it.

“Drug response and prognosis prediction is our core competence. And we are proud that ImpriMed is the only provider of such a promising solution powered by artificial intelligence in this sector. We believe that by employing machine learning, the complex, cumbersome process of quantifying the probabilities of each patient’s responses and survival specific to each drug can be done more precisely and accurately. We are committed to enhancing care and clinical outcome of canine lymphoma by assisting the processes of individualized treatment selection”, says Dr. Sungwon Lim,  CEO and Co-founder of ImpriMed.

The proprietary technology developed by ImpriMed provides a precise drug response and prognosis prediction report. This report offers tailored insights for each individual patient. After analyzing a significant amount of data including both patients’ information such as age and their live cancer cell analytics, ImpriMed’s AI-powered model predicts efficacy of thirteen drugs that are commonly used to treat canine lymphoma.

In order to ensure the accuracy of its predictions, ImpriMed analyzes real-world, clinical outcomes of thousands of patients. In addition, ImpriMed also ensures an unprecedented turnaround time of a week or less when it comes to providing analysis results and predictive information for the given patient. It helps both the pet owners and the oncologists save valuable time and initiate the treatment as early as possible.  

The service provided by ImpriMed has earned a significant reputation among oncologists and pet owners. Acknowledging the expertise of the company and the impact of its methodology on patients, several scientific journals featured ImpriMed’s technology. “We are extremely happy about the response we receive from the stakeholders. Within a short time since our inception, we have successfully contributed to improved outcomes of canine cancer patients. With our data-driven drug response prediction, we are committed to providing an improved cancer treatment methodology in the field of veterinary medicine” says Dr. Jamin Koo, Director and Co-founder.

Another notable aspect of the services provided by ImpriMed is its paperless approach and commitment to digitization. Pet owners and oncologists are provided with convenience throughout the process. The user-friendly website enables the users to access each step of the process from submitting the sample to receiving the result. Utilizing its proprietary transport media, ImpriMed also ensures that the viability of the live cancer cells is preserved during sample transportation. It ensures cells remain intact and results obtained are accurate.  

The overwhelmingly positive feedback from pet owners is a testament to ImpriMed’s commitment and the impact of its methodology. Commenting on the experience with ImpriMed, the owner of patient Yoki said, “The ImpriMed test helped us make treatment decisions with Dr. Choy. It was tremendously helpful for us. We would recommend ImpriMed to other pet parents. Veterinary oncologists are experts in this field and we heavily relied on Dr. Choy to make treatment decisions for Yoki. We are confident in the treatment Yoki is getting and are happy for the time we are getting to spend with him”  

Driven by an unwavering commitment and with an exceptional methodology, ImpriMed continues to transform the lives of many pets and their owners. ImpriMed’s drug response prediction technology revolutionizes the way we used to approach canine cancer and its treatment. Looking forward, the company seeks to expand its veterinary services to cats as well as dogs. Even further into ImpriMed’s future, its aims are to address human cancer types utilizing their expertise in live-cell analysis and AI.

In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Early leukemia and lymphoma remissions in cats and dogs

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →